Neurocrine Biosciences Q2 adjusted EPS beats expectations, revenue rises on product portfolio growth
NBIX•Guidance and analyst view
Neurocrine Biosciences raised 2026 INGREZZA net sales guidance to $2.825 billion-$2.875 billion.
The company expects 2026 GAAP research and development expense of $1.275 billion-$1.325 billion and GAAP selling, general and administrative expense of $1.575 billion-$1.6 billion.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 26 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell".
The average consensus recommendation for the pharmaceuticals peer group is "buy".
Wall Street's median 12-month price target for Neurocrine Biosciences, Inc. is $200.00, about 10.6% above its July 29 closing price of $180.79.
The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 20 three months ago.
Quarterly results beat expectations
Neurocrine Biosciences said second-quarter revenue rose 39% year over year, driven by product portfolio growth.
Adjusted earnings per share and adjusted net income for the quarter both beat analyst expectations.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Product Sales | $954.30 million | ||
| Q2 Adjusted EPS | Beat | $2.85 | $1.34 (18 Analysts) |
| Q2 EPS | $1.39 | ||
| Q2 Adjusted Net Income | Beat | $297 million | $141.43 million (18 Analysts) |
| Q2 Net Income | $144 million |
